Compare Illinois Tool Works Inc. (ITW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Illinois Tool Works Inc. trades at $271.66 (market cap $78.17B), while Vertex Pharmaceuticals Incorporated trades at $484.27 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Illinois Tool Works Inc. pays a 2.37% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ITW | VRTX | |
|---|---|---|
Market Cap | $78.17B | $121.95B |
Sector | Industrials | Health |
52-Week High | $299.60 | $529.59 |
52-Week Low | $241.07 | $366.54 |
Enterprise Value | $86.49B | $116.69B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $271.58, down 1.62% today, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 19.32% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights mixed sentiment, with some analysts citing premium valuation concerns while others note growth prospects from enterprise initiatives and a potential bullish chart pattern.
Outlook remains cautiously optimistic with a consensus price target of $288.25 offering ~6% upside. Key risks include valuation sensitivity, organic sales pressure in some segments, and macroeconomic headwinds. The upcoming Q2 2026 earnings report on July 28, 2026, will be critical for validating growth trajectory amid analyst divergence.
Vertex Pharmaceuticals (VRTX) trades at $480.51, down 1.06% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a 35.51% net income margin and robust cash flow, though it faces a recent earnings miss. A major $10 billion acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology portfolio, adding potential for significant future revenue growth.
The outlook remains positive with an 85.71% analyst buy rating and a $538 consensus price target, implying 12% upside. Key risks include integration challenges from the acquisition and reliance on cystic fibrosis treatments. Earnings growth and successful pipeline execution are critical catalysts for sustained appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
